These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 2597177)
21. Kinetics and inhibition studies of catechol O-methyltransferase from the yeast Candida tropicalis. Veser J J Bacteriol; 1987 Aug; 169(8):3696-700. PubMed ID: 3611026 [TBL] [Abstract][Full Text] [Related]
22. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. Engelbrecht I; Petzer JP; Petzer A Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034 [TBL] [Abstract][Full Text] [Related]
23. Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2- nitrophenyl)vinyl]phenyl ketone. Pérez RA; Fernández-Alvarez E; Nieto O; Piedrafita FJ J Enzyme Inhib; 1994; 8(2):123-31. PubMed ID: 7539072 [TBL] [Abstract][Full Text] [Related]
25. Calcium inhibition of rat liver catechol-O-methyltransferase. Weinshilboum RM; Raymond FA Biochem Pharmacol; 1976 Mar; 25(5):573-9. PubMed ID: 8053 [No Abstract] [Full Text] [Related]
26. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Chen D; Wang CY; Lambert JD; Ai N; Welsh WJ; Yang CS Biochem Pharmacol; 2005 May; 69(10):1523-31. PubMed ID: 15857617 [TBL] [Abstract][Full Text] [Related]
33. Catechol O-methyltransferase. 2. In vitro inhibition by substituted 8-hydroxyquinolines. Borchardt RT J Med Chem; 1973 Apr; 16(4):382-7. PubMed ID: 4736750 [No Abstract] [Full Text] [Related]
34. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Lerner C; Masjost B; Ruf A; Gramlich V; Jakob-Roetne R; Zürcher G; Borroni E; Diederich F Org Biomol Chem; 2003 Jan; 1(1):42-9. PubMed ID: 12929389 [TBL] [Abstract][Full Text] [Related]
35. Kinetic properties of a soluble catechol O-methyltransferase of human liver. Ball P; Knuppen R; Haupt M; Breuer H Eur J Biochem; 1972 Apr; 26(4):560-9. PubMed ID: 5025932 [No Abstract] [Full Text] [Related]
36. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. Brannan T; Prikhojan A; Yahr MD J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195 [TBL] [Abstract][Full Text] [Related]
37. Pyridoxal-5'-phosphate--an inhibitor of catechol-O-methyltransferase in vitro. Black IB Biochem Pharmacol; 1971 Apr; 20(4):924-7. PubMed ID: 5571025 [No Abstract] [Full Text] [Related]
38. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Meyer MR; Maurer HH Chem Res Toxicol; 2009 Jun; 22(6):1205-11. PubMed ID: 19462939 [TBL] [Abstract][Full Text] [Related]
39. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697 [TBL] [Abstract][Full Text] [Related]
40. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]